Literature DB >> 34025191

Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma.

Naruo Tokuyasu1, Masataka Amisaki1, Takehiko Hanaki1, Yuki Murakami1, Masaki Morimoto1, Ei Uchinaka1, Takuki Yagyu1, Keisuke Goto1, Tomoyuki Matsunaga1, Manabu Yamamoto1, Shuichi Takano1, Teruhisa Sakamoto1, Soichiro Honjo1, Toshimichi Hasegawa1, Yoshiyuki Fujiwara1.   

Abstract

BACKGROUND: As antithrombin III (AT-III) is produced in the hepatocytes, its serum activity decreases at the time of liver failure, in addition to ischemia reperfusion injury, vascular endothelial dysfunction, and disseminated intravascular coagulation (DIC). Here, we examined whether the serum AT-III value after hepatectomy could be a prognostic factor for hepatocellular carcinoma (HCC).
METHODS: Of 141 patients who underwent hepatectomy for HCC, data for 101 patients in whom serum AT-III activity was measured on the first postoperative day were extracted. Patients with serum AT-III activity > 50% and ≤ 50% were assigned to high value (72 cases) and low value (29 cases) groups, respectively. We examined the clinical and prognostic differences between these two groups.
RESULTS: The average age of enrolled patients (83 men and 18 women) was 68.0 years. The 5-year overall survival rate was 88% and 60% in the high and low value groups, respectively (P < 0.01). Furthermore, the 2-year relapse-free survival rate was 71% and 54% in the high and low value groups, respectively (P = 0.03).
CONCLUSION: This is the first study to demonstrate that serum AT-III levels on the first postoperative day may serve as a prognostic factor in HCC patients. ©2021 Tottori University Medical Press.

Entities:  

Keywords:  Antithrombin III; Hepatectomy; Hepatocellular carcinoma; Prognostic factor

Year:  2021        PMID: 34025191      PMCID: PMC8128657          DOI: 10.33160/yam.2021.05.007

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  32 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

Review 2.  [DIC: state-of-the-art in diagnosis and management].

Authors:  Hidesaku Asakura
Journal:  Rinsho Ketsueki       Date:  2019

3.  Antithrombin prevents apoptosis by regulating inflammation in the liver in a model of cold ischemia/warm reperfusion injury.

Authors:  Sevil Isik; Pars Tuncyurek; Neslihan Inci Zengin; Ali Eba Demirbag; Fuat Atalay; Sezai Yilmaz; Taner Orug
Journal:  Hepatogastroenterology       Date:  2012 Mar-Apr

4.  Expression of protease-activated receptors and tissue factor in human liver.

Authors:  Anne Rullier; Nathalie Senant; Walter Kisiel; Paulette Bioulac-Sage; Charles Balabaud; Brigitte Le Bail; Jean Rosenbaum
Journal:  Virchows Arch       Date:  2005-09-29       Impact factor: 4.064

Review 5.  Venous thromboembolism and prognosis in cancer.

Authors:  Alok A Khorana
Journal:  Thromb Res       Date:  2010-01-25       Impact factor: 3.944

6.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.

Authors:  F Fourrier; C Chopin; J Goudemand; S Hendrycx; C Caron; A Rime; A Marey; P Lestavel
Journal:  Chest       Date:  1992-03       Impact factor: 9.410

7.  Early coagulation disorders after severe burn injury: impact on mortality.

Authors:  Athina Lavrentieva; Theodore Kontakiotis; Militsa Bitzani; Georgia Papaioannou-Gaki; Angeliki Parlapani; Olimpia Thomareis; Nicolaos Tsotsolis; Maria-Amalia Giala
Journal:  Intensive Care Med       Date:  2008-01-12       Impact factor: 17.440

8.  Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma.

Authors:  Masataka Amisaki; Hiroaki Saito; Naruo Tokuyasu; Teruhisa Sakamoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2018-03-29

9.  Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites.

Authors:  H Honegger; N Anderson; L A Hewitt; J L Tullis
Journal:  Thromb Haemost       Date:  1981-08-28       Impact factor: 5.249

10.  Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.

Authors:  David Pereyra; Florian Offensperger; Florian Klinglmueller; Stefanie Haegele; Lukas Oehlberger; Thomas Gruenberger; Christine Brostjan; Patrick Starlinger
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.